Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result
Sara M. Cunningham, Chief Executive Officer of Benitec, stated "We are working closely with the manufacturing team to resolve this unanticipated result and will move forward as quickly as possible with the IND filing. Although the result is unrelated to the safety or efficacy of the drug, we will not file the IND until we are certain that all components of the clinical materials are fully and properly characterized and pass our stringent manufacturing criteria."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.